Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

NCT00078455 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: ILX651

Sponsor

Genzyme, a Sanofi Company